is tirzepatide a glp-1 receptor agonist Frontiers Tirzepatide (Mounjaro/Zepbound): Research Guide |

When the combinations are chosen correctly and run on a supervised schedule, the results from each compound reinforce rather than compete with one another

The resulting anemia is known as megaloblastic anemia and is the symptom for which the disease, pernicious anemia, was named (3)

The standard medical protocol for tirzepatide is a single injection once every seven days

Because it activates both, it's often called a "dual agonist." The FDA has described tirzepatide (brand name Zepbound) as the first medication of its kind to activate both of these receptors for weight management, and it was approved for that use in November 2023

It essentially adds extra adaptation time before reaching therapeutic doses

The literature around survodutide is therefore useful for understanding how sponsors try to tune glucagon biology rather than simply avoid it